TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02850445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Description: Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
Study: NCT01804192

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acu-TENS
Description: Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
Study: NCT01854073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyoscine butyl bromide
Study: NCT02453932

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil and placebo identified to Tianzhi granule
Description: donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
Study: NCT00848718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206
Description: MK-2206 given by mouth (PO) on Days 1, 3, 5, and 7 of each 21-day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 PO on Day 1 of each 21-day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Administered as an IV infusion on Day 1 of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Administered daily (QD) PO in each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered as an intravenous (IV) infusion on Day 1 of every 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroid
Description: Administered PO twice a day (BID) on Days 1-3 of each 21-day cycle
Study: NCT04287075

Intervention type: PROCEDURE
Intervention: Surgical Management of Neuroma
Description: Surgical procedures targeted to treat the source of a participant's chronic, neuropathic pain
Study: NCT04197466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Exercise Group
Description: The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Exercise Group
Description: The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Exercise Group
Description: The exercise program will be tailored according to the pelvic floor muscle strength, including fast and slow contractions. The number and duration of exercises will be increased according to progress..
Study: NCT04036916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Sensorimotor Training
Description: Games/activities specifically developed to train the sensorimotor system in headset virtual reality + strengthening of the neck
Study: NCT00233935

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study: NCT00407537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine besylate/atorvastatin calcium single pill combination
Description: Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
Study: NCT01248650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nalfurafine hydrochloride
Study: NCT02682264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-03-01 cream, 1%
Description: Cortexolone 17α-propionate (USAN/INN: clascoterone) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
Study: NCT02667158

Intervention type: OTHER
Intervention: Survey to Eval Relation between Shopping and Misuse, Abuse
Description: A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion

Intervention type: OTHER
Intervention: Survey to Eval Relation between Shopping and Misuse, Abuse
Description: A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion

Intervention type: OTHER
Intervention: Survey to Eval Relation between Shopping and Misuse, Abuse
Description: A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion

Intervention type: OTHER
Intervention: Survey to Eval Relation between Shopping and Misuse, Abuse
Description: A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
Study: NCT00971048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HP828-101
Description: Topical test article applied once daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel/Hydrocolloid
Description: Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
Study: NCT02169687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: High Intensity focalized Ultrasounds
Study: NCT01985594

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: utrogestan
Description: Oral Tablet Utrogestan 400 mg daily for 2 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nifedipine
Description: Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
Study: NCT02078323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02579941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling (non pregnant)
Description: 5.4 ml of venous blood will be taken.~This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM.
Study: NCT01112371

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contractubex
Description: Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.~Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in.
Study: NCT03392688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kujala patellofemoral pain scale
Description: Kujala patellofemoral pain scale was used to evaluate knee functions of the PFP subjects.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surface EMG
Description: The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface EMG
Description: The surface EMG electrodes (silver/silver chloride, pre-gelled, Ambu Blue Sensor, Denmark) (Konrad P.) with an interelectrode distance of 20 mm between centers were used to record an EMG signal during walking. Portable 8 channel (TELEEMG, BTS, Milan, Italy) with built in x10 amplifications, 10-450 Hz bandpass and sampling rate of 1000 Hz were used for recording. The location and orientation of the electrodes for each MH (ST) and LH (BF) were identified according to SENIAM (Surface ElectromyoGraphy for the Non-Invasive Assessment of Muscles) criteria.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Q angle measurement
Description: Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Q angle measurement
Description: Q angle measurement was applied to both patellofemoral pain and control group subjects in standing position.
Study: NCT04197466

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Kinesio tape application will be performed by ligament technique to the sacral region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: External electrical stimulation will be performed in the lying, sitting, stand up positions for 30 minutes
Study: NCT04955353

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AVC-H2
Description: A total of 2.5g AVC-H2 daily (2 tablets in the morning and 2 in the evening)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 2.5g placebo daily (2 tablets in the morning and 2 in the evening)
Study: NCT02999750

Intervention type: OTHER
Group type: OTHER
Intervention: individual therapy
Description: Patient will be treated with individual therapy.
Study: NCT01315392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: delayed closure
Description: wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
Study: NCT01854073

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study: NCT04407468

Intervention type: PROCEDURE
Intervention: Prone position
Description: Position of the patient in which he is face down, for an improvement in oxygenation
Study: NCT01148680

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Islet Graft
Description: Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
Study: NCT01315392

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate wound closure
Description: traumatic and surgical wounds closed at the initial surgical intervention
Study: NCT04483830

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulodexide
Description: an oral dose of 2 capsules each day for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an oral dose of 2 capsules each day for 21 days
Study: NCT02809729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: 2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sterile saline
Description: 0.9% saline sterile by endovenous, once, at the moment of anesthetic induction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oncologic breast surgery
Description: The patient will be submitted to a conservative oncologic breast surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: oncologic breast surgery
Description: The patient will be submitted to a conservative oncologic breast surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Microbiology
Description: Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Microbiology
Description: Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
Study: NCT01282684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PLX5622
Description: PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for PLX5622.
Study: NCT01796392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EBV
Description: This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.

Intervention type: OTHER
Group type: OTHER
Intervention: Optimal Medical Management
Description: This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
Study: NCT04220788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced pharmacist service
Description: Calculation of cardiovascular risk by an online tool for discussion on the CVD risk. Pharmacist will also provide ducation on cardiovascular risk factors and healthy lifestyle. Any prescription adaptation(s), and/or recommendations where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation will be initiated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the arm will receive their care from their respective nurse, doctor or pharmacists as per usual clinic practice
Study: NCT01820598

Intervention type: DEVICE
Group type: OTHER
Intervention: Multisite NMES training during 6 weeks

Intervention type: DEVICE
Group type: OTHER
Intervention: Multisite NMES training during 6 weeks
Study: NCT05289336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transoral Laser Microsurgery
Study: NCT00261209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase
Description: Collagenase injection into adhesion restricting tendon gliding

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase injection
Description: injection of collagenase into adhesion restricting tendon gliding
Study: NCT02691052

Intervention type: OTHER
Intervention: Quality of Life questionnaire
Description: EORTC QLQ-C30 questionnaire
Study: NCT06041451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulins, Human
Description: patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Immunoglobulins, Human
Description: patients were treated with intravenous immunoglobulin(30g ivgtt qd) for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 MG Injection
Description: patients were treated with methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 MG Injection
Description: patients were treated with methylprednisolone
Study: NCT01148680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet Graft
Description: Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
Study: NCT02945085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Based Care Team
Description: Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Based Care Team
Description: Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
Study: NCT03526900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: * Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2.